Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Drug Metabolism and Bioanalysis Letters
  4. Fast Track Articles
  5. Fast Track Article
image of Bioanalytical Method Development and Validation for the Estimation of Metformin and Vildagliptin in K3EDTA Human Plasma Using HPLC-ESI-MS/MS

Abstract

Objective

A unique liquid chromatography-tendon mass spectrometric technique for the determination of metformin and vildagliptin in K3EDTA human plasma was developed and verified as per the USFDA guidelines of bioanalysis.

Methods

The chromatographic separation was achieved using a Cosmosil CN (150 x 4.6 mm, 5 µm) column with an isocratic elution pattern using 10 mM ammonium formate (pH 5.0) and methanol in the ratio of 30:70 v/v as a mobile phase. A mass spectrometer coupled with an electrospray ionization (ESI) source operating in the positive ion was used for detection. Data were obtained in the multi-reaction monitoring (MRM) acquisition mode. Metformin D6 and vildagliptin D7 were used as internal standards, with the flow rate at 1.0 mL/min throughout the experiment. The drugs were extracted by solid phase extraction (SPE) packed with Phenomenex Strata-X. Extraction of the drug was achieved using methanol: 5 mM sodium lauryl sulphate solvent mixture in equal proportions.

Results

The retention time for MET and VLG were 3.2 and 3.8 minutes individually. The drugs were extracted by SPE with good recovery of 89.44% and 87.57% for metformin and ISTD and 92.26% and 89.58% for vildagliptin and ISTD, respectively. Sample elution was performed using solid phase extraction (SPE), and this technique produced very pure extracts with good recovery rates. A liner calibration curve was found in the range of 0.5-400 ng/mL for MET and 0.2-160 ng/mL for VLG with a correlation coefficient r2 > 0.99.

Conclusion

The aforementioned technique is reliable and effective for monitoring bioequivalence investigations in human participants.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/dmbl/10.2174/0118723128357810250304055648
2025-03-19
2025-06-20

  • From This Site

    /content/journals/dmbl/10.2174/0118723128357810250304055648
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Schweizer A. Schweizer A. Minic B. Foley J. Dejager S. Combination treatment in the management of type 2 diabetes: focus on vildagliptin and metformin as a single tablet. Vasc. Health Risk Manag. 2008 4 3 481 492 10.2147/VHRM.S2503 18827867
    [Google Scholar]
  2. Setter S.M. Iltz J.L. Thams J. Campbell R.K. Metformin hydrochloride in the treatment of type 2 diabetes mellitus: A clinical review with a focus on dual therapy. Clin. Ther. 2003 25 12 2991 3026 10.1016/S0149‑2918(03)90089‑0 14749143
    [Google Scholar]
  3. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2010 33 Suppl 1 S62 S69 10.2337/dc10‑S062 20042775
    [Google Scholar]
  4. Makrilakis K. The Role of DPP-4 Inhibitors in the Treatment Algorithm of Type 2 Diabetes Mellitus: When to Select, What to Expect. Int. J. Environ. Res. Public Health 2019 16 15 2720 10.3390/ijerph16152720 31366085
    [Google Scholar]
  5. Chahal H. Chowdhury T.A. Gliptins: a new class of oral hypoglycaemic agent. QJM 2007 100 11 671 677 10.1093/qjmed/hcm081 17881415
    [Google Scholar]
  6. Moses R. Fixed combination of repaglinide and metformin in the management of type 2 diabetes. Diabetes Metab. Syndr. Obes. 2009 2 101 109 10.2147/DMSO.S4436 21437123
    [Google Scholar]
  7. Philip J. Fernandez C.J. Efficacy and Cardiovascular Safety of Meglitinides. Curr. Drug Saf. 2021 16 2 207 216 10.2174/1574886315666201026125848 33106149
    [Google Scholar]
  8. Fisman E.Z. Tenenbaum A. Antidiabetic treatment with gliptins: focus on cardiovascular effects and outcomes. Cardiovasc. Diabetol. 2015 14 1 129 10.1186/s12933‑015‑0294‑0 26415691
    [Google Scholar]
  9. Gupta V. Kalra S. Choosing a Gliptin. Indian J. Endocrinol. Metab. 2011 15 4 298 308 10.4103/2230‑8210.85583 22029001
    [Google Scholar]
  10. Gumieniczek A. Berecka-Rycerz A. Fornal E. Żyżyńska-Granica B. Granica S. Comprehensive insight into chemical stability of important antidiabetic drug vildagliptin using chromatography (LC-UV and UHPLC-DAD-MS) and spectroscopy (Mid-IR and NIR with PCA). Molecules 2021 26 18 5632 10.3390/molecules26185632 34577104
    [Google Scholar]
  11. Ayoub B.M. Elkady E.F. El-Bagary R.I. Spectrophotometric methods for the determination of sitagliptin and vildagliptin in bulk and dosage forms. Int. J. Biomed. Sci. 2011 7 1 55 61 10.59566/IJBS.2011.7055 23675221
    [Google Scholar]
  12. Wu J. Luo W. Wang X. cheng Q. Sun C. Li H. A new application of WT-ANN method to control the preparation process of metformin hydrochloride tablets by near infrared spectroscopy compared to PLS. J. Pharm. Biomed. Anal. 2013 80 186 191 10.1016/j.jpba.2013.03.004 23587532
    [Google Scholar]
  13. Habib I. Kamel M.S. Near infra-red reflectance spectroscopic determination of metformin in tablets. Talanta 2003 60 1 185 190 10.1016/S0039‑9140(03)00123‑1 18969039
    [Google Scholar]
  14. Patel R. Purohit S. Solanki R. Khunt D. Patel C. Patel R. Parikh S. Development and validation of an analytical method for trace‐level quantification of genotoxic nitrosamine impurities in losartan and hydrochlorothiazide fixed‐dose combination tablets using ultra performance liquid chromatography triple quadrupole mass spectrometry. Rapid Commun. Mass Spectrom. 2023 37 8 e9488 10.1002/rcm.9488 36740827
    [Google Scholar]
  15. Uber C.P. Pontes F.L.D. Gasparetto J.C. Francisco T.M.G. Piantavini M.S. Cardoso M.A. Pontarolo R. HPLC-MS/MS method for simultaneous quantification of vildagliptin, metformin, and metformin-related compounds in tablets. Int. J. Pharm. Pharm. Sci. 2022 6 203 207
    [Google Scholar]
  16. Alkather Z. Hailat M. Al-Shdefat R. Abu Dayyih W. Development and validation of an HPLC method for five gliptins in pharmaceutical dosage forms in finished marketed products. Curr. Pharm. Anal. 2021 17 10 1263 1271 10.2174/1573412917999201102212635
    [Google Scholar]
  17. Mahajan N. Deshmukh S. Farooqui M. Stability indicating method for known and unknown impurities profiling for vildagliptin in vildagliptin tablet. Curr. Pharm. Anal. 2021 17 10 1293 1302 10.2174/1573412917999201016094821
    [Google Scholar]
  18. Sen D.B. Baldha K. Sen A.K. Maheshwari R.A. Zanwar A.S. KP G. Pradhan P.K. Synchronized assessment of lobeglitazone sulfate and metformin hydrochloride in tablet by robust, high-performance thin-layer chromatographic method. Curr. Pharm. Anal. 2024 20 345 357 10.2174/0115734129303749240607083542
    [Google Scholar]
  19. Kotadiya R. Joshi P. Progress in analytical techniques for remogliflozin etabonate, vildagliptin and metformin hydrochloride: a recently, approved FDC. Curr. Pharm. Anal. 2023 19 2 136 162 10.2174/1573412919666221025103613
    [Google Scholar]
  20. Sethy K. Padhy G.K. Rajeswari Katta R. A green reversed phase HPLC and HPTLC methods and their validation for simultaneous estimation of remogliflozin, vildgliptin and metformin in fixed dose combination formulation. J. Liq. Chromatogr. Relat. Technol. 2023 1 1 12 10.1080/10826076.2023.2284721
    [Google Scholar]
  21. Shakoor A. Ahmed M. Ikram R. Hussain S. Tahir A. Jan B.M. Adnan A. Stability-indicating RP-HPLC method for simultaneous determination of metformin hydrochloride and vildagliptin in tablet and biological samples. Acta Chromatogr. 2020 32 1 39 43 10.1556/1326.2019.00555
    [Google Scholar]
  22. Sen A.K. Ghodasara S. Sen D.B. Maheshwari R.A. Zanwar A.S. Dumpala R.L. Evaluation of remogliflozin, vildagliptin, and metformin in tablet dosage form using modern and cost-effective UV spectroscopic methods. J. Appl. Pharm. Sci. 2023 13 9 121 132 10.7324/JAPS.2023.136050
    [Google Scholar]
  23. Al-Sabti B. Harbali J. Development and validation of an analytical method for quantitative determination of three potentially genotoxic impurities in vildagliptin drug material using HPLC‐MS. J. Sep. Sci. 2021 44 13 2587 2595 10.1002/jssc.202100136 33934507
    [Google Scholar]
  24. Krishnan B. Mishra K. Quality by design based development and validation of RP-HPLC method for simultaneous estimation of sitagliptin and metformin in bulk and pharmaceutical dosage forms. Int. J. Pharm. Investig. 2020 10 4 512 518 10.5530/ijpi.2020.4.89
    [Google Scholar]
  25. Thomas Barden A. Piccoli B.L. Volpato N.M. Steppe M. Second-order derivative uv spectrophotometric and RP-HPLC methods for the analysis of vildagliptin and application for dissolution study. Drug Analyt. Res. 2018 2 1 46 53 10.22456/2527‑2616.86511
    [Google Scholar]
  26. Gedawy A. Al-Salami H. Dass C.R. Development and validation of a new analytical HPLC method for simultaneous determination of the antidiabetic drugs, metformin and gliclazide. Yao Wu Shi Pin Fen Xi 2019 27 1 315 322 30648585
    [Google Scholar]
  27. Patel V. Pandya C. Pandya A. Patel D. Patel Z. Novel UHPLC DAD method for simultaneous determination of vildagliptin and metformin in bulk and its tablet formulation. Res. J. Pharm. Techn. 2021 14 8 4143 4150 10.52711/0974‑360X.2021.00717
    [Google Scholar]
  28. Kiran T. N. R. Parvathi P. Kumar J. N. S. Development and validation of RP-HPLC method for the simultaneous estimation of linagliptin, empagliflozin and metformin in solid dosage forms. Asian J. Pharm. Ana. 2020 10 3 117 124 10.5958/2231‑5675.2020.00021.6
    [Google Scholar]
  29. Kallem R.R. Ramesh M. Seshagirirao J.V.L.N. Validated LC‐ESI‐MS/MS method for simultaneous quantitation of felodipine and metoprolol in rat plasma: application to a pharmacokinetic study in rats. Biomed. Chromatogr. 2013 27 6 784 791 10.1002/bmc.2861 23303553
    [Google Scholar]
  30. Koseki N. Kawashita H. Niina M. Nagae Y. Masuda N. Development and validation for high selective quantitative determination of metformin in human plasma by cation exchanging with normal-phase LC/MS/MS. J. Pharm. Biomed. Anal. 2005 36 5 1063 1072 10.1016/j.jpba.2004.09.007 15620533
    [Google Scholar]
  31. Gite S. Patravale V. Validation of RP-HPLC method and stress degradation for the combination of metformin HCl, atorvastatin calcium and glimepiride: application to nanoparticles. J. Chromatogr. Sci. 2015 53 10 1654 1662 10.1093/chromsci/bmv068 26071607
    [Google Scholar]
  32. Mansoory N.M. Jain A. Simultaneous Estimation of Metformin Hydrochloride, Pioglitazone Hydrochloride and Gliclazide by Validated RP-HPLC Method in Solid Dosage Form. Int. J. Pharm. Pharm. Sci. 2012 4 72 76
    [Google Scholar]
  33. Ben-Saghroune H. Sbai H. Abdessadek M. El attari A. Achour S. El Bouazzaoui A. Kanjaa N. Simple HPLC-UV method for the quantification of bupivacaine in human plasma with one step protein precipitation. Med. Palliat. 2020 19 3 126 133 10.1016/j.medpal.2020.01.005
    [Google Scholar]
  34. Lakshmi K.S. Rajesh T. Sharma S. Simultaneous determination of metformin and pioglitazone by reversed phase HPLC in pharmaceutical dosage forms. Int. J. Pharm. Pharm. Sci. 2009 1 162 166
    [Google Scholar]
  35. Jain D. Jain S. Jain D. Amin M. Simultaneous estimation of metformin hydrochloride, pioglitazone hydrochloride, and glimepiride by RP-HPLC in tablet formulation. J. Chromatogr. Sci. 2008 46 6 501 504 10.1093/chromsci/46.6.501 18647470
    [Google Scholar]
  36. Wang Y. Tang Y. Gu J. Fawcett J.P. Bai X. Rapid and sensitive liquid chromatography?tandem mass spectrometric method for the quantitation of metformin in human plasma. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2004 808 2 215 219 10.1016/j.jchromb.2004.05.006 15261814
    [Google Scholar]
  37. Ashutosh K.S. Manidipa D. Seshagiri R. Gowri S.D. New validated stability indicating RP-HPLC method for simultaneous estimation of metformin and alogliptin in human plasma. J. Chromatogr. Sep. Tech. 2015 6 1 6
    [Google Scholar]
  38. Kharabe P.M. Jumade P.P. Khatale P.N. Katolkar P.P. Butle S.R. Kshirsagar M.D. Pendharkar V.V. Sawale A.V. Choudhari K.S. Reverse phase, ion exchange, HILIC and mix-mode chromatography for the determination of metformin and evogliptin in human plasma and pharmaceutical formulations. Talanta Open 2024 9 100274 10.1016/j.talo.2023.100274
    [Google Scholar]
  39. Gumieniczek A. Berecka-Rycerz A. Mroczek T. Wojtanowski K. Determination of chemical stability of two oral antidiabetics, metformin and repaglinide in the solid state and solutions using LC-UV, LC-MS, and FT-IR methods. Molecules 2019 24 24 4430 10.3390/molecules24244430 31817112
    [Google Scholar]
  40. ALquadeib B.T. Aloudah N.M. Almurshedi A.S. ALfagih I.M. ALdosari B.N. ALmeleky A.S. Almubyedh N.M. Development and validation of a simple and sensitive LC-MS/MS method for quantification of metformin in dried blood spot its application as an indicator for medication adherence. Int. J. Gen. Med. 2021 14 3225 3233 10.2147/IJGM.S312633 34267540
    [Google Scholar]
  41. Adhi Pradana D. Kristin E. Nugroho A.K. Nugrahaningsih D.A.A. Mustofa M. Wibowo A. Bioanalytical method Validation of metformin hydrochloride in human plasma by HPLC-UV for preliminary Population-Based Pharmacokinetic Modeling study. Indones. J. Chem. 2023 23 4 937 10.22146/ijc.77903
    [Google Scholar]
  42. Patel M.M. Patel D. Shah U. Kachhiya H.M. A simple, precise, and sensitive RP-HPLC Method for quantification of teneligliptin hydrobromide and metformin hydrochloride: development and validation. Res. J. Pharm. Tech. 2023 16 2 495 501 10.52711/0974‑360X.2023.00084
    [Google Scholar]
  43. Rana K. Sharma P. Analytical method development and validation for the simultaneous estimation of metformin hydrochloride and alogliptin by RP-HPLC in bulk and tablet dosage forms. Res. J. Sci. Tech. 2021 13 2 111 118 10.52711/2349‑2988.2021.00017
    [Google Scholar]
  44. Gollu G. Gummadi S. A rapid LC-PDA method for the simultaneous quantification of metformin, empagliflozin and linagliptin in pharmaceutical dosage form. Ann. Pharm. Fr. 2022 80 1 48 58 10.1016/j.pharma.2021.06.003 34157314
    [Google Scholar]
  45. Sirisha R. Vasanth P.M. Ramesh T. Malothu R. Rp-Hplc method development and validation for simultaneous estimation of metformin and sitagliptin in tablet dosage forms. Int. J. Chem. Tech. Res. 2020 6 1 15 10.20902/IJCTR.2018.111149
    [Google Scholar]
  46. Vetapalem R. Yejella R.P. Atmakuri L.R. Development and validation of a stability indicating RP-HPLC method for simultaneous estimation of teneligliptin and metformin. Turk. J. Pharm. Sci. 2020 17 2 141 147 10.4274/tjps.galenos.2018.16768 32454773
    [Google Scholar]
  47. Pharne A.B. Santhakumari B. Ghemud A.S. Jain H.K. Kulkarni M.J. Bioanalytical method development and validation of vildagliptin a novel dipeptidyl peptidase Iv inhibitor by RP-HPLC method. Int. J. Pharm. Pharm. Sci. 2012 4 119 123
    [Google Scholar]
  48. Barden A.T. Salamon B. Schapoval E.E.S. Steppe M. Stability-indicating RP-LC method for the determination of vildagliptin and mass spectrometry detection for a main degradation product. J. Chromatogr. Sci. 2012 50 5 426 432 10.1093/chromsci/bms024 22511486
    [Google Scholar]
  49. de Andrade C. de Araújo Lock G. Pigatto M.C. Haas S.E. Costa T.D. de Araújo B.V. Validation of LC‐MS/MS method applied to evaluation of free tissue concentrations of vildagliptin in diabetic rats by microdialysis. Biomed. Chromatogr. 2014 28 12 1722 1727 10.1002/bmc.3212 24771661
    [Google Scholar]
  50. Satya Raga Devi A. Ashutosh Kumar S. Saravanan J. Debnath M. Greeshma V. Sai Krishna N. Rao C.N.M. A new RP-HPLC method development for simultaneous estimation of metformin and gliclazide in bulk as well as in pharmaceutical formulation by using PDA detector. Res. J. Pharm. Technol. 2014 7 142 150
    [Google Scholar]
  51. Muruganathan G. Thangavel M. Kochupapy R.T. Stability-Indicating HPTLC method for determination of remogliflozin etabonate and vildagliptin in tablets. J. Chromatogr. Sci. 2023 62 1 27 34 10.1093/chromsci/bmad001 36670546
    [Google Scholar]
  52. Arar S. Al-Qudah E. Alzweiri M. Sweidan K. New forced degradation products of vildagliptin: Identification and structural elucidation using LC-MS, with proposed formation mechanisms. J. Liq. Chromatogr. Relat. Technol. 2020 43 15-16 633 644 10.1080/10826076.2020.1779084
    [Google Scholar]
  53. Prajapati P. Rana B. Pulusu V.S. Shah S. Simultaneous chromatographic estimation of vildagliptin and dapagliflozin using hybrid principles of white analytical chemistry and analytical quality by design. J. AOAC Int. 2024 107 1 212 222 10.1093/jaoacint/qsad108 37698979
    [Google Scholar]
  54. Patel B.H. Teraiya N.H. Simultaneous estimation and stability indicating method of vildagliptin and dapagliflozin by RP-HPLC in pharmaceutical dosage form. Int. Inter. Med. J. 2024 2 4 01 06 10.21203/rs.3.rs‑4080300/v1
    [Google Scholar]
  55. Al-Qudah E. Arar S. Sweidan K. Forced degradation studies of vildagliptin raw material alone and in the presence of excipients using HPLC-UV analysis. J. Excip. Food Chem. 2020 11 2 29 41
    [Google Scholar]
  56. Bendale A.R. Singh R.P. Vidyasagar G. Development and validation stability indicating Hptlc method for determination of vildagliptin and metformin hydrochloride in the pharmaceutical dosage forms. Int. J. Appl. Pharma. 2018 10 1 36 45 10.22159/ijap.2018v10i1.20555
    [Google Scholar]
  57. Pontarolo R. Gimenez A.C. de Francisco T.M.G. Ribeiro R.P. Pontes F.L.D. Gasparetto J.C. Simultaneous determination of metformin and vildagliptin in human plasma by a HILIC–MS/MS method. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2014 965 133 141 10.1016/j.jchromb.2014.06.023 25016166
    [Google Scholar]
  58. Satheeshkumar N. Pradeepkumar M. Shanthikumar S. Rao V.J. Development of validated stability indicating assay method for simultaneous estimation of metformin hydrochloride and vildagliptin by RP-HPLC. Drug Res. (Stuttg.) 2014 64 3 124 129 24081820
    [Google Scholar]
  59. Al Bratty M. Alhazmi H.A. Javed S.A. Lalitha K.G. Asmari M. Wölker J. El Deeb S. Development and validation of LC–MS/MS method for simultaneous determination of metformin and four gliptins in human plasma. Chromatographia 2017 80 6 891 899 10.1007/s10337‑017‑3288‑0
    [Google Scholar]
  60. El-Zaher A.A. Hashem H.A. Elkady E.F. Allam M.A. A validated LC-MS/MS bioanalytical method for the simultaneous determination of dapagliflozin or saxagliptin with metformin in human plasma. Microchem. J. 2019 149 104017 10.1016/j.microc.2019.104017
    [Google Scholar]
  61. Dayyih W.A. Hamad M. Mallah E. Dayyih A.A. Awad R. Zakaria Z. Arafat T. Method development and validation of vildagliptin and metformin HCl in pharmaceutical dosage form by reversed phase-high performance liquid chromatography (RP-HPLC). Int. J. Pharm. Sci. Res. 2018 9 2965 2972
    [Google Scholar]
  62. Sai Prudhvi N. Venkateswarlu B.S. Kumudhavalli M.V. Muruganantham V. Novel stability indicating LC-MS/MS method for the simultaneous estimation of remogliflozin etabonate and vildagiption human plasma. J. Med. Pharm. Alli. Sci. 2021 10 5 3718 3725 10.22270/jmpas.V10I5.1655
    [Google Scholar]
  63. Mohite P. Bhusal R. Khandre Y. Pandhare R. Pawar A. A new gas chromatographic method for quantification of Metformin hydrochloride and Vildagliptin in bulk and pharmaceutical dosage form: development and validation. Future J. Pharm. Sci. 2024 10 1 62 10.1186/s43094‑024‑00635‑z
    [Google Scholar]
  64. Elgawish M.S. Nasser S. Salama I. Abbas A.M. Mostafa S.M. Liquid chromatography tandem mass spectrometry for the simultaneous determination of metformin and pioglitazone in rat plasma: Application to pharmacokinetic and drug-drug interaction studies. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2019 1124 47 57 10.1016/j.jchromb.2019.05.036 31177048
    [Google Scholar]
  65. Kulkarni P. Karanam A. Gurjar M. Dhoble S. Naik A.B. Vidhun B.H. Gota V. Effect of various anticoagulants on the bioanalysis of drugs in rat blood: implication for pharmacokinetic studies of anticancer drugs. Springerplus 2016 5 1 2102 10.1186/s40064‑016‑3770‑4 28053832
    [Google Scholar]
  66. Wang L. Shang K. Feng T. Dong W. Wang F. Shen X. LC–MS/MS method assay for simultaneous determination of the apixaban and metformin in rat plasma: assessment of pharmacokinetic drug–drug interaction study. J. Chromatogr. Sci. 2022 61 6 522 529 10.1093/chromsci/bmac076 36097794
    [Google Scholar]
  67. Lou Y. Qin H. Hu Q. Chai Y. Zhou H. Chen M. Wang Q. Huang P. Gu J. Zhang Y. Development and validation of a novel LC-MS/MS method for simultaneous quantitative determination of tyrosine kinase inhibitors in human plasma. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2022 1208 123394 10.1016/j.jchromb.2022.123394 35932695
    [Google Scholar]
  68. Tomášová P. Bugáňová M. Pelantová H. Holubová M. Šedivá B. Železná B. Haluzík M. Maletínská L. Kuneš J. Kuzma M. Metabolomics based on MS in mice with diet-induced obesity and type 2 diabetes mellitus: the effect of vildagliptin, metformin, and their combination. Appl. Biochem. Biotechnol. 2019 188 1 165 184 10.1007/s12010‑018‑2899‑8 30393821
    [Google Scholar]
  69. Arbouche N. Raul J.S. Kintz P. Development of a new LC-MS/MS method for the simultaneous identification and quantification of 13 antidiabetic drugs in human hair. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2022 1205 123335 10.1016/j.jchromb.2022.123335 35716545
    [Google Scholar]
  70. Narikimalli A. Galla R. AQbD based approach for UPLC procedure development for the concurrent quantification of Metformin, Vildagliptin, Dapagliflozin and Sitagliptin in bulk and tablets: Response surface methodology paradigm. Anal. Chem. Lett. 2024 14 4 528 548 10.1080/22297928.2024.2376118
    [Google Scholar]
  71. Shah P.A. Shrivastav P.S. Vanol P.G. Sanyal M. Mechanistic study for the simultaneous determination of metformin and teneligliptin in human plasma using hydrophilic interaction liquid chromatography-MS/MS. Bioanalysis 2018 10 7 475 488 10.4155/bio‑2018‑0007 29561645
    [Google Scholar]
  72. FDA. Guidance for Industry: Bioanalytical Method Validation. 2022 Available from: http//www.fda.gov/cder/Guidance/4252fnl.pdf
  73. ICH-Q2 (R2): Validation of Analytical Procedures, International Conference on Harmonization Geneva European Medicines Agency 2022 33
    [Google Scholar]
  74. Procedures A. Methods Validation–Chemistry, Manufacturing, and Controls Documentation. US Department of Health and Human Services. Beltsville, MD Drug Information Center for Drug Evaluation and Research 2000 18
    [Google Scholar]
/content/journals/dmbl/10.2174/0118723128357810250304055648
Loading
Bioanalytical Method Development and Validation for the Estimation of Metformin and Vildagliptin in K3EDTA Human Plasma Using HPLC-ESI-MS/MS
Bentham Science Publishers ; https://doi.org/10.2174/0118723128357810250304055648
/content/journals/dmbl/10.2174/0118723128357810250304055648
/content/journals/dmbl/10.2174/0118723128357810250304055648
Loading

Data & Media loading...


  • Article Type:     Research Article
Keywords: metformin (MET) ; multi-reaction monitoring ; vildagliptin (VLG) ; LC-MS/MS ; Bioanalysis ; solid phase extraction (SPE)

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test